GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » Price-to-Owner-Earnings

Regulus Therapeutics (STU:7RG0) Price-to-Owner-Earnings : (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-16), Regulus Therapeutics's share price is €1.86. Regulus Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Regulus Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


STU:7RG0's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.045
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-16), Regulus Therapeutics's share price is €1.86. Regulus Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.34. Therefore, Regulus Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-16), Regulus Therapeutics's share price is €1.86. Regulus Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.34. Therefore, Regulus Therapeutics's PE Ratio without NRI for today is At Loss.


Regulus Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Regulus Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Price-to-Owner-Earnings Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regulus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regulus Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Regulus Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Price-to-Owner-Earnings falls into.



Regulus Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Regulus Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.86/-0.99
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regulus Therapeutics  (STU:7RG0) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Regulus Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics (STU:7RG0) Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Regulus Therapeutics (STU:7RG0) Headlines

No Headlines